4IOV

The structure of AAVrh32.33, a Novel Gene Delivery Vector

4IOV の概要

• エントリーDOI: 10.2210/pdb4iov/pdb
• 分子名称: Capsid protein VP1, 2'-DEOXYADENOSINE-5'-MONOPHOSPHATE (2 entities in total)
• 機能のキーワード: beta barrel icosahedral capsid, viral capsid, plasma, virus
• 由来する生物種: Adeno-associated virus
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 81485.78

構造登録者

Mikalism, K.,Nam, H.-J.,Van vilet, K.,Vandenberghe, L.H.,Mays, L.E.,McKenna, R.,Wilson, J.,Agbandje-McKenna, M. (登録日: 2013-01-08, 公開日: 2014-04-02, 最終更新日: 2024-02-28)

主引用文献

Mikals, K.,Nam, H.J.,Van Vliet, K.,Vandenberghe, L.H.,Mays, L.E.,McKenna, R.,Wilson, J.M.,Agbandje-McKenna, M.
The structure of AAVrh32.33, a novel gene delivery vector.
J.Struct.Biol., 186:308-317, 2014

PubMed Abstract: The Adeno-associated viruses (AAVs) are being developed as gene delivery vectors for therapeutic clinical applications. However, the host antibody immune response directed against their capsid, prevalent in ∼40-70% of the general population, depending on serotype, negatively impacts efficacy. AAVrh32.33, a novel vector developed from rhesus macaques isolates, has significantly lower seroprevalence in human populations compared to AAV2 and AAV8, which are both in clinical use. To better understand the capsid determinants of this differential immune response to AAVrh32.33, its structure was determined by X-ray crystallography to 3.5 Å resolution. The capsid viral protein (VP) structure conserves the eight-stranded β-barrel core and αA helix reported for other parvoviruses and the distinct capsid surface topology of the AAVs: a depression at the icosahedral twofold axis, three protrusions surrounding the threefold axis, and a depression surround a cylindrical channel at the fivefold axis. A comparison to AAV2, AAV4, and AAV8, to which AAVrh32.33 shares ∼61%, ∼81%, and ∼63% identity, respectively, identified differences in previously defined AAV VP structurally variable regions (VR-1 to VR-IX) which function as receptor attachment, transduction efficiency, and/or antigenic determinants. This structure thus provides a 3D platform for capsid engineering in ongoing efforts to develop AAVrh32.33, as well as other AAV serotypes, for tissue targeted gene-therapy applications with vectors that can evade pre-existing antibody responses against the capsid. These features are required for full clinical realization of the promising AAV gene delivery system.

PubMed: 24704217
DOI: 10.1016/j.jsb.2014.03.020

実験手法

X-RAY DIFFRACTION (3.5 Å)